OMER
vs
S&P 500
OMER
S&P 500
Over the past 12 months, OMER has outperformed S&P 500, delivering a return of +22% compared to the S&P 500's +14% growth.
Stocks Performance
OMER vs S&P 500
Performance Gap
OMER vs S&P 500
Performance By Year
OMER vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Omeros Corp
Glance View
Omeros Corp. operates as a biopharmaceutical company. The company is headquartered in Seattle, Washington and currently employs 213 full-time employees. The company went IPO on 2009-10-08. The firm is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, immunologic diseases and cancers. The Company’s lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome and coronavirus (COVID-19). OMS906, the Company’s inhibitor of MASP-3, the alternative pathway of complement, is in a Phase 1 clinical trial.
